The cancer receptor we selected as the target is the human epidermal growth factor receptor 2 (HER2), a member of the epidermal growth factor receptor (EGFR) family, which is overexpressed in about 25 to 30% of breast and ovarian cancers as well as in a variety of other tumors, including stomach cancer, lung cancer, and glioblastoma (20). Here, ERBB2 is linked to ovarian carcinoma.